Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey

What Was Tested

Researchers studied Bradykinin and Icatibant in this observational study publication.

To report IOS data comparing demographic and icatibant treatment outcomes in patients with HAE-C1-INH from Germany to HAE-C1-INH patients from 11 other IOS countries.

Who Took Part

The study group was 685 patients.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

A descriptive, retrospective, comparative analysis of data from 685 IOS patients with HAE-C1-INH from seven centres in Germany (n = 93) vs. centres from Austria, Brazil, Czech Republic, Denmark, France, Greece, Israel, Italy, Spain, Sweden and the United Kingdom (n = 592, July 2009-January 2017).

Icatibant treatment outcomes were retrieved from patients with complete attack outcome data for time to treatment, time to resolution and attack duration (160 attacks in 42 German patients and 1442 attacks in 251 patients from other IOS countries).

What Was Measured

The subject headings attached to it are Angioedemas, Hereditary, Bradykinin, Bradykinin B2 Receptor Antagonists, Germany, Health Surveys, Symptom Flare Up and Time-to-Treatment.

What This Means in Plain Language

This is an observational study of Bradykinin and Icatibant in 685 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Journal of the European Academy of Dermatology and Venereology : JEADV), a journal based in England.

More context: the Bradykinin compound page and the Icatibant compound page, all human trials.